041960 — Komipharm International Co Income Statement
0.000.00%
- KR₩294bn
- KR₩328bn
- KR₩43bn
Annual income statement for Komipharm International Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | — | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 35,490 | 37,160 | 35,847 | 39,801 | 42,647 |
Cost of Revenue | |||||
Gross Profit | 11,417 | 13,376 | 11,234 | 11,459 | 12,658 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 48,968 | 40,033 | 41,489 | 43,790 | 49,018 |
Operating Profit | -13,478 | -2,873 | -5,642 | -3,990 | -6,371 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -13,851 | -3,957 | -5,934 | -7,480 | -5,739 |
Provision for Income Taxes | |||||
Net Income After Taxes | -23,267 | -3,957 | -5,934 | -7,480 | -5,911 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -21,363 | -2,816 | -4,459 | -6,514 | -3,979 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -21,363 | -2,816 | -4,459 | -6,514 | -3,979 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -231 | -32.2 | -58.4 | -90 | -56.4 |
Dividends per Share |